|
ChemDiv Signs an Agreement with SatRx, UCSD and Moscow Institute of Physics and Technology to Jointly Conduct R&D for T2D drugs
San Diego, CA - June 8, 2013. The Russian biopharmaceutical company "SatRx" specializing in the development of innovative drugs for the treatment of diabetes and metabolic syndromes, the University of California at San Diego (UCSD), The Moscow Institute of Physics and Technology’s Biopharmaceutical cluster “Northern” (BPCN@MIPT) and ChemDiv Research Institute signed an agreement to conduct joint research on the development of innovative drugs for the treatment of type 2 diabetes (T2D).
The partnership provides access to specific pharmacological models of UCSD in conjunction with translational research for the development of innovative non-systemic agonists of TGR-5 receptors produced by scientists at MIPT, SatRX and CDRI.
The non-systemic TGR-5 agonist program is currently in preclinical development. Selected candidates will enter clinical trials and advance into Russian and global markets.
TGR-5 receptors play a key role in mediating the secretion of glucagon like peptide 1 (GLP-1) by enteroendocrine L-cells which increase insulin secretion. The increase in insulin levels normalize blood glucose levels and other critical biochemical and metabolic abnormalities leading to a therapeutic effect in patients with T2D. At the present time, incretin-based therapies are globally accepted, and are a promising approach in T2D treatment. The non-systemic stimulation of intestinal TGR-5 receptors is aimed to approach similar anti-diabetic efficacy with an increase in safety profile.
SatRx LLC, a Russian biopharmaceutical company with a novel non-systemic TGR-5 agonist program in the pipeline, announced that Dr. Jerrold M. Olefsky, Professor of Medicine at the University of California, San Diego (UCSD), has joined its Scientific Advisory Board. Dr. Olefsky is a renowned endocrinologist with expertise in molecular mechanisms of T2D, metabolic syndrome and other pathophysiologic states accompanying insulin resistance.
Dr. Olefsky is a Professor of Medicine, an Assistant Dean of Science and Technology at UCSD and co-chairs the Division of Endocrinology and Metabolism at the UCSD School of Medicine. Dr. Olefsky’s main focus is the molecular and cellular mechanisms of insulin and IGF-I. The main emphasis of his research is the elucidation of the structure/function relationship of the related receptors for these ligands.
Dr.Olefsky co-founded Metabolex, Inc. and serves as a member of the Scientific Advisory Board at NGM Biopharmaceuticals, Inc., Sirtris Pharmaceuticals Inc., Biodel Inc. and DiObex Inc. Dr. Olefsky has over 350 publications and serves on the Editorial Board of Endocrinology and Diabetes. Dr. Olefsky has received the American Diabetes Association’s Banting Medal for Scientific Achievement, as well as the Canadian Diabetes Association’s Best Award, The Endocrine Society’s Edwin Astwood Award, the Elliott P. Joslin Medal, and the Mayo Soley Award of the Western Society for Clinical Investigation.
Prof. Olefsky’s expertise in Endocrinology in collaboration with Russia's leading institute of higher education - MIPT, the University of California at San Diego, "SatRX" and ChemDiv Research Institute is anticipated to contribute to the development of a new generation of safe and effective anti-diabetic therapies.
Contact for media:
Olga Dmitrieva
Director of Marketing, ChemDiv
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
Washington, DC, April 24, 2013 – The Moscow Institute of Physics and Technology Biopharmaceutical cluster “Northern” (BPCN@MIPT), the Wisconsin Technology Innovation Initiative, Inc. (Wi2) (formed to support the University of Wisconsin School of Medicine and Public Health), and ChemDiv Research Institute announced the signing of a Memorandum of Understanding (MOU) to form a non-exclusive consortium developing innovative therapeutics aimed at improvement of human and animal health. The official signing ceremony was held at the U.S.-Russia Innovation Working Group Meeting with the participation of Vladislav Surkov, Deputy Prime Minister of the Russian Federation; Robert D. Hormats, Under-Secretary for Economic Growth, Energy and the Environment of the USA; Oleg Fomichev, Deputy Minister of Economic Development of the Russian Federation; and others.
The overall aim of this Research and Development consortium is to jointly develop and market molecules, biological materials, medical devices, diagnostics, and other technologies and data resulting from Wi2, BPCN@MIPT and ChemDiv technologies. These platforms may include specialized training of research and clinical personnel, software programs and databases for digital healthcare.
Wi2 is a one of a kind non-profit organization formed to facilitate the translation of innovations into applied uses. The work of Wi2 is done in collaboration with the private sector, the University of Wisconsin-Madison, and other institutions nationally and internationally.
In accordance with the agreement terms, Wi2 will provide access to technologies in the fields of cancer, neurodegenerative diseases, and metabolic diseases, and will facilitate the transition of innovative technology developed at the University of Wisconsin into the marketplace. Wi2 will organize and finance a Translational Development Team (TDT) for each research platform through contributions by the other parties, grants obtained by Wi2, and, in the longer term, royalties derived from licensing of technologies resulting for the pre-commercialization efforts.
BPCN@MIPT provides access to technologies in the fields of biomed engineering and biophysics and innovative pharmaceuticals development. BPCN@MIPT also provides technological platforms and access to a highly diverse group of researchers of Moscow Institute of Physics and Technology (MIPT) and other cluster members including biophysicists, chemists, biochemists as well as computational scientists, advancing the interdisciplinary field of physics and the biophysics of excitable and self-organizing systems.
ChemDiv Research Institute, as a global CRO with 20 years experience in the life science industry, is a leading provider of integrated services to major pharmaceutical and biotech companies. ChemDiv grants access to its proprietary technologies such as protein engineering, production, structural biology and structure-based drug discovery, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK and multiple in vivo efficacy/toxicology models.
BPCN@MIPT and ChemDiv will jointly promote the collaborative platforms to a pre-approved set of global partners (including major pharmaceutical and biotechnology companies).
“We are very enthusiastic about this partnership. It is important to us to build and leverage international networks in order to be on the frontier of research, education, and innovation”, said Oleg Korzinov, Executive Director of BPCN@MIPT. “Now, building this subsequent three way relationship with ChemDiv and Wi2 is of exceptional value due to their unique expertise and high profile. We are confident that this is the start of a strong and synergistic collaboration that will yield novel technologies and treatments for diseases with unmet medical needs.”
Richard L Moss, PhD, U.W. Professor and Chief Scientific Officer of Wi2: “We are delighted with the new partnership for the opportunities it provides in the commercialization of innovative platform technologies originating from the School of Medicine and Public Health (University of Wisconsin), from our consortium partners, and elsewhere. Global outreach and public-private partnerships have the potential to promote the translation of discoveries from the laboratory to clinical care. This agreement promises to accelerate translation and address the needs of rapidly growing markets. The Moscow Institute of Physics and Technology is a world-class research institution in Russia and a strong ally in commercialization, with advanced capabilities in infrastructure, fundamental expertise, and essential human resources in research and development. We are also very excited about our private partner, ChemDiv, which is leading CRO focused on developing pharmaceutical in Russia”.
Contact for media:
Elena Surina
PR Director, Biopharmaceutical cluster “Northern”
E-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
|
|
ChemDiv Receives Multiple Milestones in Major Drug Discovery Collaboration with Eli Lilly
San Diego, CA, USA - 19 December 2012: ChemDiv, Inc., a fully integrated drug discovery and development contract research organization with research facilities in San Diego, USA and Moscow, Russia, announced receipt of several milestones across three major therapeutic areas resulting from its collaboration with Eli Lilly. Financial details were not disclosed.
Alex Kiselyov, Ph.D., President of ChemDiv commented: “Using our integrated drug discovery platforms, team of chemists and biologists at ChemDiv, Inc. identified multiple active series to supplement therapeutic programs at Eli Lilly. This is yet another step in our successful collaborative efforts with pharma and biotech partners to identify advanced preclinical drug candidates.”
About ChemDiv
ChemDiv, Inc. is a Fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the world. It engages pharmaceutical and biotech partners by offering 'one stop' drug discovery and development services based on a project-, FTE- and risk sharing collaborative modes. ChemDiv has ongoing R&D collaborations in a number of functional areas and across multiple therapeutic platforms with Abbott Laboratories, Johnson & Johnson, Mitsubishi Tanabe, UCB as well as research contracts in programs of ChemRar Group in partnerships with Pfizer, Hoffman-La Roche and others. More info about ChemDiv is available at www.chemdiv.com. |
|
 
11/07/2012 - San Diego, CA - COARE Biotechnology (COARE) and ChemDiv, Inc. (ChemDiv) announced today the formation of a strategic alliance that will offer a fully integrated gene-to-clinic services aimed at development of therapeutic agents that selectively affect cancer stem cells (CSC).
|
|
San Diego, CA – June 26, 2012 - ChemDiv is pleased to announce the appointment of Alex Kiselyov as its President.
|
|
June 14, 2012 San Diego – Brussels – Moscow - UCB and ChemDiv have successfully concluded the first phase of their 2011 collaborative discovery chemistry program executed with ChemDiv’s Moscow subsidiary, the ChemDiv Research Institute.
|
|
ChemDiv, Inc. signs research and collaboration agreement with Janssen Pharmaceutica NV and Tibotec Pharmaceuticals for integrated drug discovery projects
|
|
ChemDiv Research Institute (CDRI) at the ChemRar Hi-Tech Centre announced that it has signed collaboration and license option agreement with the Singapore based Novartis Institute for Tropical Diseases (NITD) to undertake discovery and development of patentable chemical compounds to find new, faster cures for Tuberculosis.
|
|
San Diego, California, August 20th, 2011 - ChemDiv,Inc (www.chemdiv.com), global provider of the world’s largest collection of commercially available small-molecule compounds, announced today that it has entered into an Exclusive Distribution Agreement with Shanghai Topscience Co., Ltd, (www.tsbiochem.com), a China based company focused on sales and marketing of chemical libraries for drug discovery needs.
|
|
Pfizer And Chemrar High Tech Center Announce Plans To Explore
Innovative Medical Research And Development Partnership In Russia
Collaboration Focused on Addressing Unmet Medical Needs of Patients in Cancer, Cardiovascular, Central Nervous System, and Other Major Therapeutic Areas that Impact the Russian Population
|
|
|
What's New
